# AIIMS Delhi Develops Affordable Antibody-Based Therapy for Recurrent Multiple Myeloma AIIMS Delhi has made a significant breakthrough in cancer treatment by developing an affordable antibody-based therapy for recurrent cancers, particularly Multiple Myeloma (MM). This innovation, spearheaded by the Department of Medical Oncology at BRAIRCH, aims to make advanced therapies like CAR-T cell treatment more accessible in India. Multiple Myeloma, a cancer affecting plasma cells in bone marrow, often relapses after initial treatment. CAR-T cell therapy, a revolutionary treatment that genetically modifies a patient's T cells to target and destroy cancer cells, has shown remarkable success but remains prohibitively expensive for most Indian patients, costing over Rs 1 crore. AIIMS researchers have addressed this challenge by creating an indigenous therapy using an antibody targeting BCMA, a critical marker for MM. This antibody, developed by Dr. Mayank Singh and his team, has been successfully patented in India. The researchers plan to initiate clinical trials soon, aiming to reduce the therapy's cost to around Rs 20 lakh. This development offers new hope for Indian patients with recurrent MM, who often face limited treatment options due to high costs. The AIIMS-developed therapy could transform cancer care in India, making advanced immunotherapy more accessible to a larger population. https://www.linkedin.com/company/strategic-market-studies/?viewAsMember=true https://www.linkedin.com/company/agropluss/?viewAsMember=true https://www.linkedin.com/company/market-research-nexus-pro/?viewAsMember=true https://www.linkedin.com/company/trending-articles/?viewAsMember=true https://www.linkedin.com/company/clarity-market-insights/?viewAsMember=true https://www.linkedin.com/company/market-analytics-hub/?viewAsMember=true https://www.linkedin.com/company/market-visionary-group/?viewAsMember=true https://www.linkedin.com/company/precision-market-lab/?viewAsMember=true https://www.linkedin.com/company/markets-mind/about/?viewAsMember=true https://www.linkedin.com/company/trendseeker-research/about/?viewAsMember=true